Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | BlueCross BlueShield of Tennessee | Steroid-Eluting and Non-Steroid-Eluting Sinus Stents | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Talimogene Laherparepvec (Imlygic) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Tremelimumab-actl (Imjudo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Imetelstat (Rytelo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Tarlatamab-dlle (Imdelltra) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Nipocalimab-aahu (Imaavy) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Tildrakizumab-asmn (Ilumya) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Image-Guided Minimally Invasive Decompression for Spinal Stenosis | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Travoprost Intracameral Implant (iDose TR) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ibalizumab-uiyk (Trogarzo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Hospital-Grade Breast Pump | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Home Spirometry | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Home Apnea Monitoring / Home Cardiorespiratory Monitoring | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Histrelin Acetate (Supprelin LA) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Hippotherapy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Trastuzumab Products (Herceptin, Ontruzant, Herzuma, Ogivri, Trazimera, Kanjinti, Hercessi) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Hematopoietic Stem-Cell Transplantation for Miscellaneous Solid Tumors in Adults | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Hematopoietic Progenitor Cell (HPC) Boost | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Hair Transplantation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Guselkumab (Tremfya) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Goserelin Acetate (Zoladex) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Golodirsen (Vyondys-53) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Golimumab (Simponi ARIA) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Givosiran (Givlaari) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Genetic Testing for Warfarin Dose | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Genetic Testing for Mitochondrial Disorders | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Connective Tissue Disorders | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Novel Biomarkers for the Diagnosis and Management of Prostate Cancer | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Genetic Testing for Mental Health Conditions | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Gene Expression Profile Analysis for Prostate Cancer Management | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Gender Reassignment Surgery | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Gemtuzumab Ozogamicin (Mylotarg) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Gemcitabine (Inlexzo) intravesical system | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | DOCUMENTATION | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Galsulfase (Naglazyme) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Fractional Laser Treatment of Vulvovaginal Atrophy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Fosdenopterin (Nulibry) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pralatrexate (Folotyn); Pralatrexate | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | MRI-Guided Focal Laser Ablation for Prostate Cancer | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Fluocinolone Acetonide Implant (Yutiq) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Fluocinolone Acetonide Implant (Retisert) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Fluocinolone Acetonide Implant (Iluvien) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | First-Trimester Detection of Down Syndrome Using Fetal Ultrasound Markers Combined with Maternal Serum Assessment | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Icatibant (Firazyr), Icatibant (Sajazir), Icatibant | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Fetal Surgery for Prenatally Diagnosed Malformations | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Surgical Treatment of Femoroacetabular Impingement | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Faricimab-svoa (Vabysmo) | Criteria changed |